Even as the biotech financing environment improves, investors maintain high standards. The challenge isn't finding investors but building enough conviction to make them invest. Capital is available, but not easily accessible to all.
Instead of a one-size-fits-all approach, biotech leaders should first identify their next logical investor. Then, they should tailor their clinical strategy and milestones to directly address the uncertainties that specific investor class needs resolved.
Biotech leaders should focus on experiments that will quickly determine if a drug "hunts or doesn't." Spending millions on studies that confirm existing beliefs, while leaving major risks unaddressed, is a common and costly fundraising pitfall.
Once viewed negatively as a "breach of birth," reverse mergers are now a credible and efficient path to the public markets for biotech companies. They can compress timelines and save money, rivaling traditional IPOs in legitimacy.
Strategic partnerships are often touted as non-dilutive. While they don't affect the cap table, they give away a portion of a program's future economics. This reduces the company's intrinsic value, a critical trade-off leaders must acknowledge.
A company's cash runway is a powerful tool in negotiations. A longer runway (e.g., 18 months vs. 6) provides critical leverage, allows for a more competitive process, and prevents making deals from a position of desperation with investors or partners.
Biotech leaders shouldn't "fall on their knife" to avoid dilution. The objective isn't survival; it's financing the company to a value-changing event. No company fails from dilution, but many fail from being underfunded to reach a key milestone.
Previously, being fourth or fifth to market could still lead to blockbuster success. Now, with Chinese biotechs excelling at creating "me-better" drugs, laggard companies risk becoming "brand generics" pre-launch, underscoring the need for genuine differentiation.